Elanco Animal Health Inc. (ELAN) — closed signal from July 17, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on October 15, 2025.
Predicted vs. what happened
What happened
Reached its target in 41 days.
The thesis — published July 17, 2025
Investment bank Leerink now rates Elanco as a top pick. Option prices imply traders expect a sharp swing when results arrive on 7-Aug. After months of falling, the share price looks beaten down and could climb to 19-20 dollars within three months if sales and profits beat expectations. A 400 million-dollar cost-cut program and several new animal medicines give extra fuel. With fewer sellers left, any good news could spark a quick jump.
Primary drivers
- Leerink's new top pick rating boosts market mood and draws fresh interest.
- Extremely low reading hints the sell-off may be done, allowing tight exit plans.
- Costly options suggest traders expect a big price swing at earnings time.
- Saving 400 million dollars should widen profits as fresh products reach customers.
How it played out
ELAN: target reached in 41 days
Lyra published ELAN at $14.87 on 2025-07-17 with a short-term setup that expected 25% growth. The thesis pointed to Leerink's top pick rating, a beaten-down share price, costly options around 7-Aug results, a 400 million-dollar cost-cut program, and fresh animal medicines as possible fuel for a move toward the target.
Inside the window, ELAN reached a peak of $21.76 on 2025-10-07, a 46.3% gain. The target price of $18.59 was reached in 41 days. The stock ended the window at $20.51. The thesis played out, and the move went beyond the published target.
What happened during the window
On Aug. 8, 2025, Investor's Business Daily reported that ELAN's Relative Strength Rating rose from 77 to 89. The same article said sales growth improved from -1% to 5%.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.